These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
621 related articles for article (PubMed ID: 28423558)
1. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558 [TBL] [Abstract][Full Text] [Related]
2. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
3. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
5. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
6. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
7. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Choi J; Lee JH; Koh I; Shim JK; Park J; Jeon JY; Yun M; Kim SH; Yook JI; Kim EH; Chang JH; Kim SH; Huh YM; Lee SJ; Pollak M; Kim P; Kang SG; Cheong JH Oncotarget; 2016 Oct; 7(40):65643-65659. PubMed ID: 27582539 [TBL] [Abstract][Full Text] [Related]
8. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399 [TBL] [Abstract][Full Text] [Related]
9. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906 [TBL] [Abstract][Full Text] [Related]
10. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862 [TBL] [Abstract][Full Text] [Related]
11. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
12. Sulforaphane enhances temozolomide-induced apoptosis because of down-regulation of miR-21 via Wnt/β-catenin signaling in glioblastoma. Lan F; Pan Q; Yu H; Yue X J Neurochem; 2015 Sep; 134(5):811-8. PubMed ID: 25991372 [TBL] [Abstract][Full Text] [Related]
13. A Metabolic Inhibitory Cocktail for Grave Cancers: Metformin, Pioglitazone and Lithium Combination in Treatment of Pancreatic Cancer and Glioblastoma Multiforme. Elmaci İ; Altinoz MA Biochem Genet; 2016 Oct; 54(5):573-618. PubMed ID: 27377891 [TBL] [Abstract][Full Text] [Related]
14. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors. Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243 [TBL] [Abstract][Full Text] [Related]
15. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235 [TBL] [Abstract][Full Text] [Related]
16. Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. Sun Q; Pei C; Li Q; Dong T; Dong Y; Xing W; Zhou P; Gong Y; Zhen Z; Gao Y; Xiao Y; Su J; Ren H Biochem Biophys Res Commun; 2018 Feb; 496(4):1040-1046. PubMed ID: 29366782 [TBL] [Abstract][Full Text] [Related]
17. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901 [TBL] [Abstract][Full Text] [Related]
18. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype. Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956 [TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499 [TBL] [Abstract][Full Text] [Related]
20. Metformin treatment reduces temozolomide resistance of glioblastoma cells. Yang SH; Li S; Lu G; Xue H; Kim DH; Zhu JJ; Liu Y Oncotarget; 2016 Nov; 7(48):78787-78803. PubMed ID: 27791206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]